CPRX vs. HRMY, EVO, GPCR, SDGR, SUPN, AGIO, GLPG, ZLAB, AVDL, and NAMS
Should you be buying Catalyst Pharmaceuticals stock or one of its competitors? The main competitors of Catalyst Pharmaceuticals include Harmony Biosciences (HRMY), Evotec (EVO), Structure Therapeutics (GPCR), Schrödinger (SDGR), Supernus Pharmaceuticals (SUPN), Agios Pharmaceuticals (AGIO), Galapagos (GLPG), Zai Lab (ZLAB), Avadel Pharmaceuticals (AVDL), and NewAmsterdam Pharma (NAMS). These companies are all part of the "pharmaceutical preparations" industry.
Harmony Biosciences (NASDAQ:HRMY) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, community ranking, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.
Harmony Biosciences has a net margin of 22.30% compared to Harmony Biosciences' net margin of 15.83%. Catalyst Pharmaceuticals' return on equity of 28.26% beat Harmony Biosciences' return on equity.
86.2% of Harmony Biosciences shares are owned by institutional investors. Comparatively, 79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. 30.8% of Harmony Biosciences shares are owned by company insiders. Comparatively, 11.0% of Catalyst Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
In the previous week, Catalyst Pharmaceuticals had 12 more articles in the media than Harmony Biosciences. MarketBeat recorded 15 mentions for Catalyst Pharmaceuticals and 3 mentions for Harmony Biosciences. Catalyst Pharmaceuticals' average media sentiment score of 1.76 beat Harmony Biosciences' score of 0.32 indicating that Harmony Biosciences is being referred to more favorably in the media.
Harmony Biosciences has a beta of 0.75, meaning that its share price is 25% less volatile than the S&P 500. Comparatively, Catalyst Pharmaceuticals has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500.
Catalyst Pharmaceuticals received 442 more outperform votes than Harmony Biosciences when rated by MarketBeat users. Likewise, 74.31% of users gave Catalyst Pharmaceuticals an outperform vote while only 60.29% of users gave Harmony Biosciences an outperform vote.
Harmony Biosciences currently has a consensus target price of $40.63, indicating a potential upside of 32.03%. Catalyst Pharmaceuticals has a consensus target price of $26.71, indicating a potential upside of 64.80%. Given Harmony Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Catalyst Pharmaceuticals is more favorable than Harmony Biosciences.
Harmony Biosciences has higher revenue and earnings than Catalyst Pharmaceuticals. Harmony Biosciences is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Harmony Biosciences and Catalyst Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks.
Get Catalyst Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CPRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Catalyst Pharmaceuticals Competitors List
Related Companies and Tools
